Your browser is no longer supported. Please, upgrade your browser.
SAGE Sage Therapeutics, Inc. daily Stock Chart
Sage Therapeutics, Inc.
Index- P/E- EPS (ttm)-12.46 Insider Own0.10% Shs Outstand51.91M Perf Week-0.21%
Market Cap2.25B Forward P/E- EPS next Y-9.19 Insider Trans0.00% Shs Float50.95M Perf Month19.06%
Income-643.60M PEG- EPS next Q-2.66 Inst Own- Short Float12.96% Perf Quarter47.85%
Sales8.70M P/S258.16 EPS this Y-65.50% Inst Trans-2.00% Short Ratio6.27 Perf Half Y-43.62%
Book/sh16.36 P/B2.62 EPS next Y8.20% ROA-56.60% Target Price73.88 Perf Year-77.37%
Cash/sh16.68 P/C2.57 EPS next 5Y13.10% ROE-63.10% 52W Range25.01 - 193.56 Perf YTD-40.55%
Dividend- P/FCF- EPS past 5Y-51.60% ROI-75.00% 52W High-77.83% Beta2.69
Dividend %- Quick Ratio12.80 Sales past 5Y- Gross Margin93.40% 52W Low71.61% ATR2.04
Employees675 Current Ratio12.80 Sales Q/Q360.00% Oper. Margin- RSI (14)58.19 Volatility4.65% 5.29%
OptionableYes Debt/Eq0.00 EPS Q/Q27.50% Profit Margin- Rel Volume0.52 Prev Close44.11
ShortableYes LT Debt/Eq0.00 EarningsMay 07 AMC Payout- Avg Volume1.05M Price42.92
Recom2.00 SMA204.91% SMA5010.34% SMA200-41.78% Volume545,779 Change-2.70%
May-08-20Downgrade Wedbush Outperform → Neutral
Apr-08-20Downgrade Guggenheim Buy → Neutral
Mar-18-20Upgrade RBC Capital Mkts Sector Perform → Outperform $73 → $60
Mar-06-20Initiated Citigroup Buy $71
Feb-28-20Reiterated H.C. Wainwright Neutral $87 → $78
Feb-06-20Initiated Mizuho Neutral
Dec-06-19Reiterated RBC Capital Mkts Outperform $190 → $100
Dec-05-19Reiterated Guggenheim Buy $200 → $110
Dec-05-19Downgrade SunTrust Buy → Hold
Oct-30-19Initiated H.C. Wainwright Neutral $160
May-23-19Initiated Wedbush Outperform
Apr-25-19Initiated Jefferies Buy $195
Dec-14-18Initiated Wolfe Research Outperform
Oct-11-18Initiated Oppenheimer Outperform $170
Aug-07-18Reiterated Stifel Buy $198 → $239
Aug-06-18Initiated Piper Jaffray Overweight $206
Jun-06-18Initiated Ladenburg Thalmann Buy $230
Mar-26-18Resumed Canaccord Genuity Buy $210
Feb-26-18Initiated Morgan Stanley Overweight
Dec-08-17Reiterated Needham Buy $100 → $193
Jun-24-20 03:58PM  
Jun-17-20 04:04PM  
Jun-10-20 08:37PM  
Jun-09-20 09:55AM  
Jun-01-20 06:30AM  
May-09-20 05:01PM  
May-08-20 06:30AM  
May-07-20 04:01PM  
May-03-20 07:30PM  
Apr-22-20 11:09AM  
Apr-21-20 07:39AM  
Apr-20-20 07:48AM  
Apr-16-20 06:30AM  
Apr-13-20 10:51AM  
Apr-08-20 12:29PM  
Apr-07-20 04:01PM  
Apr-03-20 04:30PM  
Mar-27-20 02:53PM  
Mar-20-20 08:30PM  
Mar-19-20 06:57PM  
Mar-18-20 06:30AM  
Mar-12-20 08:45AM  
Mar-11-20 07:00AM  
Mar-04-20 04:30PM  
Mar-02-20 09:59AM  
Feb-27-20 07:39PM  
Feb-26-20 08:31AM  
Feb-25-20 12:03PM  
Feb-24-20 06:30AM  
Feb-10-20 06:30AM  
Feb-04-20 04:30PM  
Feb-03-20 11:27AM  
Jan-17-20 08:40AM  
Jan-09-20 08:44AM  
Jan-03-20 04:30PM  
Dec-29-19 03:24AM  
Dec-23-19 02:47PM  
Dec-19-19 03:07PM  
Dec-16-19 11:28AM  
Dec-14-19 02:56PM  
Dec-12-19 08:15PM  
Dec-11-19 08:01PM  
Dec-10-19 09:18PM  
Dec-09-19 10:20AM  
Dec-06-19 03:00PM  
Dec-05-19 08:31PM  
Dec-04-19 09:28AM  
Dec-03-19 04:30PM  
Nov-25-19 06:44PM  
Nov-20-19 06:10PM  
Nov-15-19 10:02AM  
Nov-12-19 06:31AM  
Nov-11-19 04:30PM  
Nov-05-19 06:00PM  
Oct-30-19 01:49PM  
Oct-23-19 02:29PM  
Oct-20-19 06:06PM  
Oct-14-19 03:42AM  
Oct-09-19 06:18PM  
Oct-03-19 10:52AM  
Oct-02-19 04:30PM  
Sep-20-19 02:04PM  
Sep-05-19 04:31PM  
Sep-04-19 05:05PM  
Sep-03-19 05:31PM  
Aug-14-19 12:35PM  
Aug-06-19 06:30AM  
Aug-05-19 04:30PM  
Sage Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone that has completed Phase III clinical trials for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and sleep disorders; and SAGE-324, a novel neuroactive steroid that has completed Phase I clinical trials to treat various neurological conditions, including essential tremor and epileptiform disorders. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain; and SAGE-689, a novel GABAA receptor positive allosteric modulator that is in preclinical stage to treat acute and chronic CNS disorders. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
IGUCHI KIMICFO & TreasurerApr 30Option Exercise1.364,0005,44033,261May 04 04:53 PM
IGUCHI KIMICFO & TreasurerDec 10Option Exercise1.3650068029,261Dec 10 09:26 PM
Robichaud AlbertChief Scientific OfficerDec 09Option Exercise20.1215,743316,746111,400Dec 10 08:04 PM
IGUCHI KIMICFO & TreasurerDec 09Option Exercise1.3615,00020,40028,761Dec 10 09:26 PM
JONAS JEFFREY MPresident & CEODec 09Buy64.207,500481,50054,530Dec 10 08:04 PM
Robichaud AlbertChief Scientific OfficerDec 09Buy64.1625,0001,604,000136,400Dec 10 08:04 PM
JONAS JEFFREY MPresident & CEOSep 11Option Exercise0.454,6002,07047,030Sep 12 05:00 PM
Kanes StephenChief Medical OfficerSep 04Option Exercise0.456,0002,7008,292Sep 05 04:33 PM
FRATES JAMES MDirectorAug 15Option Exercise28.358,000226,80010,535Aug 16 04:04 PM
FRATES JAMES MDirectorAug 15Sale160.588,0001,284,6402,535Aug 16 04:04 PM
IGUCHI KIMICFO & TreasurerJul 25Option Exercise1.362,0002,72012,409Jul 25 06:02 PM
IGUCHI KIMICFO & TreasurerJul 17Option Exercise1.364,0005,44010,409Jul 17 04:02 PM
JONAS JEFFREY MPresident & CEOJul 16Option Exercise0.4527,00012,15039,115Jul 17 04:01 PM